Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $38 price target.
February 28, 2024 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Pliant Therapeutics with a maintained $38 price target.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst suggests a positive outlook for Pliant Therapeutics, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100